Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.31 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6320199 | 0.88 | PKM (0.31) | PKMMAPKAPK2PDE3BPDE3A | |
| SCHEMBL6325709 | 0.78 | PTK2 (0.37) | PTK2OPRD1CDC7CCNE1CDK2 | |
| SCHEMBL6319582 | 0.76 | LMNA (0.31) | — | |
| SCHEMBL6325622 | 0.75 | EPHX2 (0.34) | PKMPTK2MAPKAPK2GRIA1CACNG8 | |
| SCHEMBL6325348 | 0.74 | GRIA1 (0.32) | PKMPTK2MAPKAPK2GRIA1CACNG8 | |
| SCHEMBL6323006 | 0.72 | PDE3B (0.33) | PTK2MAPKAPK2GRIA1CACNG8OPRD1 | |
| SCHEMBL6319203 | 0.69 | GRIA1 (0.34) | PTK2MAPKAPK2GRIA1CACNG8CDC7 | |
| SCHEMBL6318789 | 0.69 | MAP3K11 (0.35) | MAPKAPK2GRIA1CACNG8OPRD1PDE3B | |
| SCHEMBL6268096 | 0.68 | GRIA1 (0.33) | MAPKAPK2GRIA1CACNG8CDC7CCNE1 | |
| SCHEMBL6256396 | 0.68 | EPHX2 (0.32) | MAPKAPK2GRIA1CACNG8OPRD1SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | QUATRX PHARMACEUTICALS CO. | 2005-06-30 | — | — | US | claimed |
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | QUATRX PHARMACEUTICALS CO. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | APOB, LDLR, LPL | PKM 1878/4885PTK2 1567/4885MAPKAPK2 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.